Cover image of Crohn’s & Colitis Foundation Perspectives
(6)
Health & Fitness
Medicine
Science

Crohn’s & Colitis Foundation Perspectives

Updated 5 days ago

Health & Fitness
Medicine
Science
Read more

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD.The Crohn’s Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.  In Collaboration with

Read more

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD.The Crohn’s Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.  In Collaboration with

iTunes Ratings

6 Ratings
Average Ratings
4
1
1
0
0

iTunes Ratings

6 Ratings
Average Ratings
4
1
1
0
0
Cover image of Crohn’s & Colitis Foundation Perspectives

Crohn’s & Colitis Foundation Perspectives

Updated 5 days ago

Read more

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.With 1.6 million Americans living with IBD, which includes Crohn’s disease and ulcerative colitis, and approximately 70,000 new cases diagnosed annually, the Crohn’s Colitis Foundation is dedicated to developing and cultivating IBD healthcare providers through continued education and creation of valuable resources that directly impact the standard-of-care and everyday clinical practices in IBD.The Crohn’s Colitis Foundation is the only national organization dedicated to driving efforts in IBD research, education and support for patients, caregivers, and professionals.  The Crohn’s Colitis Foundation is building initiatives to address high priority areas, and developing the tools, including this educational series, to educate healthcare professionals and meet patients’ needs.  In Collaboration with

Rank #1: Gut Feeling: The Links Between IBD and Mental Health

Podcast cover
Read more
Host: Adam Ehrlich, MD, MPH
Guest: Alison Kaufman, PsyD

Our body responds to stress and anxiety in a variety of ways. For patients with IBD, the body manifests stress into various psychological issues, creating a link between IBD and mental health.

Dr. Alison Kaufman, a psychologist at Children’s Hospital of Philadelphia will discuss the common emotional reactions of IBD patients, suggesting ways for physicians to help these patients cope with their chronic disease. She is joined by Dr. Adam Ehrlich of Temple University.

Jul 07 2017
Play

Rank #2: Diet Nutrition in the Management of IBD

Podcast cover
Read more
Host: Lu Ann Cahn
Guest: James D. Lewis, MD, MSCE

Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges?

Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.

Mar 18 2019
Play

Rank #3: Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complications

Podcast cover
Read more
Host: Lea Ann Chen, MD
Guest: Gary Lichtenstein, MD

Recorded on location at the Crohn’s & Colitis Foundation’s Annual Meeting in Orlando, host Dr. Lea Ann Chen, Assistant Professor of Medicine at New York University, discusses potential complications of biologics with Dr. Gary Lichtenstein, Professor of Medicine at the Hospital of the University of Pennsylvania.

Feb 27 2017
Play

Rank #4: IBD Preventive Care: Clinical Priorities for Best Patient Outcomes

Podcast cover
Read more
Host: Brian P. McDonough, MD, FAAFP
Guest: Adam Ehrlich, MD, MPH
Guest: John D. Betteridge, MD

From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Brian McDonough leads an expert panel focusing on preventive care for IBD patients. Joining the expert panel are:

  • Dr. Adam C. Ehrlich, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Co-Medical Director of the Temple Inflammatory Bowel Disease Program, and
  • Dr. John D. Betteridge, Gastroenterologist at Lancaster General Hospital and Regional Gi Medical Center. Drs. Ehrlich and Betteridge discuss the issues surrounding IBD with a focus on preventative care in patients.

Discussion points include micronutrient deficiencies, immunosuppression, methods to maintain a well-balanced nutrient-rich diet, and communication strategies between PCPs and GI specialists to improve patient care.

Apr 12 2018
Play

Rank #5: Emerging 'Bowel-Sparing' Procedures for Crohn's Disease

Podcast cover
Read more
Host: Jennifer Caudle, DO
Guest: Fabrizio Michelassi, MD

As a gastrointestinal surgeon and Chairman of Surgery at Weill Cornell, Dr. Fabrizio Michelassi has witnessed the possible complications that can stem from Crohn's disease. He joins Dr. Jennifer Caudle to provide his perspective on new surgical approaches to treat strictures and fibrostenotic complications.

Feb 15 2019
Play

Rank #6: The Latest Treatment Options for IBD Patients

Podcast cover
Read more
Host: Rebecca Kaplan
Guest: Adam Ehrlich, MD, MPH

As new treatment options become available for IBD patients, it is important to be informed on which treatments will work best for which patient populations. Dr. Adam Ehrlich, Assistant Professor of Medicine at Temple University School of Medicine, joins Rebecca Kaplan to discuss what's coming down the drug pipeline for patients with IBD. He will touch on the recent medication approvals of biologics and biosimilars, as well as how IBD treatments are moving closer to precision medicine.

Jul 07 2017
Play

Rank #7: Crohn’s Colitis Congress: Nutritional Therapy for IBD: From Theory to Your Practice

Podcast cover
Read more
Host: Kelly Issokson, MS, RD, CNSC
Guest: James D. Lewis, MD, MSCE

After the “Nutritional Therapy for IBD: From Theory to Your Practice” session at the second annual Crohn’s & Colitis Congress in Las Vegas, dietician Kelly Issokson and Dr. James Lewis recap the key takeaways, how you can implement those takeaways into your practice, and the benefits of recruiting dieticians and other healthcare professionals to provide your IBD patients with nutritional therapy.

Apr 02 2019
Play

Rank #8: IBD: A Journey from Parent to Advocate

Podcast cover
Read more
Host: Jennifer Caudle, DO

For many IBD patients and their parents, becoming involved with advocacy groups provides an excellent support system, especially since this can be a difficult disease to manage. But some also use these groups to make a difference not only locally, but also nationally.

Sharing his personal-turned-professional journey with Dr. Jennifer Caudle is Frank Russomano, President and CEO of ReachMD, who is also joined by the President & CEO of the Crohn’s & Colitis Foundation, Michael Osso.

Sep 20 2018
Play

Rank #9: Addressing the Psychosocial Impacts of IBD

Podcast cover
Read more
Host: Eva M. Szigethy, MD, PhD
Guest: Megan E. Riehl, PsyD

Psychosocial disorders like anxiety and depression can be especially severe when combined with the physical symptoms of IBD. Fortunately, there are ways gastroenterologists, primary care providers, and mental health specialists can all work together to address these effects as early as possible, as Dr. Megan Riehl, Clinical Assistant Professor of Medicine and Clinical Psychologist at the University of Michigan, explains.

Mar 29 2019
Play

Rank #10: Extraintestinal Findings in Inflammatory Bowel Disease

Podcast cover
Read more
Host: Caren Heller, MD
Guest: Christina Y. Ha, MD

Dr. Caren Heller, Chief Scientific Officer at the Crohn’s & Colitis Foundation chats with Dr. Christina Ha, Assistant Clinical Professor of Gastroenterology at the University of California-Los Angeles about what physicians need to know regarding extraintestinal findings in IBD.

Mar 06 2017
Play

Rank #11: Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

Podcast cover
Read more

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.

Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D.

BACKGROUND:

Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure.

METHODS:

This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay.

RESULTS:

During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = ...

Jan 02 2018
Play

Rank #12: The Crohn’s Colitis Foundation's Camp Oasis: A Clinician's Perspective

Podcast cover
Read more
Host: Philip Stein, MD
Guest: Neilanjan Nandi, MD, FACP
Guest: Susan Peck, MSN, CRNP

From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Philip Stein talks with Dr. Neilanjan Nandi and nurse practitioner Susan Peck about their respective experiences with The Crohn’s & Colitis Foundation's Camp Oasis. This camp gives children with IBD the opportunity to meet other kids with the same chronic illness, teaching them how to cope with their disease, manage their own medical needs, try new sports and activities, build confidence and independence, and most importantly, spend quality time just being a kid.

Apr 12 2018
Play

Rank #13: Anemia Care for IBD Patients

Podcast cover
Read more
Host: Laura Wingate
Guest: Jason Ken Hou, MD, MS, FACG

Patients with inflammatory bowel diseases (IBD) are at a greater risk of developing anemia, a common complication that affects their quality of life and is associated with high rates of other IBD-related complications.

Host Laura Wingate, Vice President of Education, Support and Advocacy for the Crohn's & Colitis Foundation, chats with Dr. Jason Hou, Assistant Professor of Gastroenterology at Baylor College of Medicine about gaps in the importance of anemia management, diagnostics, and awareness for patients with IBD that continue to exist among healthcare providers.

Feb 27 2017
Play

Rank #14: Iron Sequestration in Microbiota Biofilms in Treatment for IBD

Podcast cover
Read more
Host: Damian Maseda, D.M.Sc., PhD

Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.

Jean-Paul Motta, PhD Thibault Allain, PhD Luke E Green-Harrison, BScRyan A Groves, MSc Troy Feener, MSc Hena Ramay, PhD Paul L Beck, MD/PhDIan A Lewis, PhD John L Wallace, PhD Andre G Buret, PhD

ABSTRACT:

Significant alterations of intestinal microbiota and anemia are hallmarks of inflammatory bowel disease (IBD). It is widely accepted that iron is a key nutrient for pathogenic bacteria, but little is known about its impact on microbiota associated with IBD. We used a model device to grow human mucosa-associated microbiota in its physiological anaerobic biofilm phenotype. Compared to microbiota from healthy donors, microbiota from IBD patients generate biofilms ex vivo that were larger in size and cell numbers, contained higher intracellular iron concentrations, and exhibited heightened virulence in a model of human intestinal epithelia in vitro and in the nematode Caenorhabditis elegans. We also describe an unexpected iron-scavenging property for an experimental hydrogen sulfide-releasing derivative of mesalamine. The findings demonstrate that this new drug reduces the virulence of IBD microbiota biofilms through ...

Mar 29 2019
Play

Rank #15: Travel for IBD Patients: How to Help Them Prepare

Podcast cover
Read more
Host: Adam Ehrlich, MD, MPH
Guest: Adam Kaufman, MD

From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Adam C. Ehrlich talks with Dr. Adam Kaufman, Gastroenterologist at Main Line Gastroenterology Associates. Dr. Kaufman brings to the forefront the importance of preparing your IBD patient for travel. Discussion points include scheduling a pre-travel counsel visit, medication choices and proper storage procedures, vaccination considerations, blood clot prophylaxis, and travel insurance.

Apr 12 2018
Play

Rank #16: Improving Care for Children with IBD

Podcast cover
Read more

From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. Jose Fernando Del Rosario, head of Pediatric Gastroenterology at the Nemours Alfred I. duPont Hospital for Children in Wilmington, DE. Dr. Del Rosario and his department are the recipients of this year’s Gold Medallion Award from the Foundation. He discusses providing a positive experience for the patient and the importance of teaching children how to manage their health while living with a chronic condition, regaining quality of life and the most recent treatments for managing IBD, including nutritional therapy.

Dec 15 2017
Play

Rank #17: A Message from the President CEO of Crohn’s Colitis Foundation

Podcast cover
Read more

Hear from Michael Osso, President and CEO of the Crohn’s & Colitis Foundation, as he talks about the Crohn’s & Colitis Foundation Perspectives series on ReachMD.

May 23 2018
Play

Rank #18: RISK Cohort Study in Crohn's Disease

Podcast cover
Read more

From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.

Dec 15 2017
Play

Rank #19: Crohn’s Colitis Congress: How to Manage Complicated IBD

Podcast cover
Read more
Host: Alessandro Fichera, MD
Guest: Judy Cho, MD

At the second annual Crohn’s & Colitis Congress in Las Vegas, Dr. Alesandro Fichera and Dr. Judy Cho discuss the session that they co-moderated about the management of complicated IBD and the breakthroughs for Crohn's disease management that could limit your patients’ need for surgery.

Apr 02 2019
Play

Rank #20: Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

Podcast cover
Read more

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.

Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.

BACKGROUND:

Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution.

METHODS:

Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation.

RESULTS:

Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...

Oct 30 2017
Play

Similar Podcasts